Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model

Fig. 4

Cytotoxicity of FD7, FD7-LPN, CCD, CCD-LPN, and Afa in different formulations on bEnd.3 and PC9 cells. Cytotoxicity of different concentrations of A FD7 and FD7-LPN, B CCD, CCD-LPN, and C Afa on bEnd.3 cells, D Afa on PC9 cells, E Afa/LPN, Afa/LPN-FD7, and Afa/LPN-CCD on bEnd.3 cells for 48 h, and F Afa/LPN, Afa/LPN-FD7, and Afa/LPN-CCD on PC9 cells for 48 h. Cell viability was measured via SRB assay. Values are the mean ± S.D. (n = 3). (A, B, E) # represents the concentrations of FD7, CCD, Afa, and Afa/LPN with low cytotoxic effects on bEnd.3 cells, which were used in the following experiments. F *statistical significance at p < 0.05; **p < 0.01; ***p < 0.001

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us